Pro Medicus holds the cards in 'high stakes' 4DMedical bet
The market darling's results will take centre stage, but a bet on an ASX minnow has set tongues wagging at the smaller end of the market.
Market darling Pro Medicus’ full year results will be closely watched on Thursday, with investors looking for evidence the $31 billion radiology software play can live up to its lofty valuation.
But a recent deal it struck with an ASX minnow has set tongues wagging at the smaller end of the market, sparking claims the deal is heavily weighted in favour of the bigger company.
Pro Medicus' $10 million debt and equity deal with 4DMedical, which aimed at accelerating approval of its lung scanning software in the US, caught the attention of sales desks last month.
PAC Partners international equity sales head James Nicolaou described it to clients in poker terms, describing 4D as going “all in” with a weak bankroll in the hopes of a big commercial win.
